Genetically Targeted T Cells Eradicate Systemic Acute Lymphoblastic Leukemia Xenografts

Purpose: Human T cells targeted to the B cell–specific CD19 antigen through retroviral-mediated transfer of a chimeric antigen receptor (CAR), termed 19z1, have shown significant but partial in vivo antitumor efficacy in a severe combined immunodeficient (SCID)-Beige systemic human acute lymphoblastic leukemia (NALM-6) tumor model. Here, we investigate the etiologies of treatment failure in this model and design approaches to enhance the efficacy of this adoptive strategy. Experimental Design: A panel of modified CD19-targeted CARs designed to deliver combined activating and costimulatory signals to the T cell was generated and tested in vitro to identify an optimal second-generation CAR. Antitumor efficacy of T cells expressing this optimal costimulatory CAR, 19-28z, was analyzed in mice bearing systemic costimulatory ligand-deficient NALM-6 tumors. Results: Expression of the 19-28z CAR, containing the signaling domain of the CD28 receptor, enhanced systemic T-cell antitumor activity when compared with 19z1 in treated mice. A treatment schedule of 4 weekly T-cell injections, designed to prolong in vivo T-cell function, further improved long-term survival. Bioluminescent imaging of tumor in treated mice failed to identify a conserved site of tumor relapse, consistent with successful homing by tumor-specific T cells to systemic sites of tumor involvement. Conclusions: Both in vivo costimulation and repeated administration enhance eradication of systemic tumor by genetically targeted T cells. The finding that modifications in CAR design as well as T-cell dosing allowed for the complete eradication of systemic disease affects the design of clinical trials using this treatment strategy.

[1]  Michel Sadelain,et al.  Targeted elimination of prostate cancer by genetically directed human T lymphocytes. , 2005, Cancer research.

[2]  É. Vivier,et al.  Selective associations with signaling proteins determine stimulatory versus costimulatory activity of NKG2D , 2002, Nature Immunology.

[3]  R. Shah,et al.  In Vivo Visualization of Metastatic Prostate Cancer and Quantitation of Disease Progression in Immunocompromised Mice , 2003, Cancer biology & therapy.

[4]  M. Croft.  Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? , 2003, Nature Reviews Immunology.

[5]  M. Debenedette,et al.  4-1BB Ligand Induces Cell Division, Sustains Survival, and Enhances Effector Function of CD4 and CD8 T Cells with Similar Efficacy1 , 2001, The Journal of Immunology.

[6]  M. Smyth,et al.  Immunotherapy of cancer using systemically delivered gene-modified human T lymphocytes. , 2004, Human gene therapy.

[7]  R. Mulligan,et al.  Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Christopher C W Hughes,et al.  Endothelial cell co-stimulation through OX40 augments and prolongs T cell cytokine synthesis by stabilization of cytokine mRNA. , 2005, International immunology.

[9]  M. Papamichail,et al.  Targeting of tumor cells by lymphocytes engineered to express chimeric receptor genes , 2004, Cancer Immunology, Immunotherapy.

[10]  P. Stern,et al.  The Role of Extracellular Spacer Regions in the Optimal Design of Chimeric Immune Receptors: Evaluation of Four Different scFvs and Antigens , 2005, Journal of immunotherapy.

[11]  H. Heslop,et al.  Current status of genetic modification of T cells for cancer treatment. , 2005, Cytotherapy.

[12]  Michel Sadelain,et al.  Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells , 2000, Nature Biotechnology.

[13]  D. Campana,et al.  Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia , 2004, Leukemia.

[14]  G. Freeman,et al.  The B7–CD28 superfamily , 2002, Nature Reviews Immunology.

[15]  B. Seliger,et al.  Tumor-Specific T Cell Activation by Recombinant Immunoreceptors: CD3ζ Signaling and CD28 Costimulation Are Simultaneously Required for Efficient IL-2 Secretion and Can Be Integrated into One Combined CD28/CD3ζ Signaling Receptor Molecule , 2004, The Journal of Immunology.

[16]  B. Seliger,et al.  Tumor-Specific T Cell Activation by Recombinant Immunoreceptors: CD3ζ Signaling and CD28 Costimulation Are Simultaneously Required for Efficient IL-2 Secretion and Can Be Integrated Into One Combined CD28/CD3ζ Signaling Receptor Molecule1 , 2001, The Journal of Immunology.

[17]  S. Larson,et al.  Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15 , 2003, Nature Medicine.

[18]  C. June,et al.  The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation. , 2005, Blood.

[19]  C. June,et al.  Costimulatory approaches to adoptive immunotherapy. , 1998, Current opinion in oncology.

[20]  David D. Smith,et al.  CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. , 2006, Cancer research.

[21]  L. Tuel-ahlgren,et al.  Biotherapy for xenografted human central nervous system leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin. , 1995, Blood.

[22]  A. Lawson,et al.  Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. , 1998, Journal of immunology.

[23]  R. Flavell,et al.  Integrated src kinase and costimulatory activity enhances signal transduction through single-chain chimeric receptors in T lymphocytes. , 2001, Blood.

[24]  A. Scott,et al.  Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Michel Sadelain,et al.  Targeting tumours with genetically enhanced T lymphocytes , 2003, Nature Reviews Cancer.

[26]  M. Croft.  Costimulation of T cells by OX40, 4-1BB, and CD27. , 2003, Cytokine & growth factor reviews.

[27]  M. Brenner,et al.  Genetic modification of T lymphocytes for adoptive immunotherapy. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[28]  A. Lawson,et al.  Activation of Resting Human Primary T Cells with Chimeric Receptors: Costimulation from CD28, Inducible Costimulator, CD134, and CD137 in Series with Signals from the TCRζ Chain , 2004, The Journal of Immunology.

[29]  Jun Wu,et al.  An activating immunoreceptor complex formed by NKG2D and DAP10. , 1999, Science.

[30]  H. Heslop,et al.  A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[31]  F. Thistlethwaite,et al.  Engineering T cells for cancer therapy , 2005, British Journal of Cancer.

[32]  Z. Eshhar,et al.  Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. , 2004, The Journal of clinical investigation.

[33]  N. Bander,et al.  Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. , 1999, Neoplasia.

[34]  Michel Sadelain,et al.  Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor , 2002, Nature Biotechnology.

[35]  M. Kuroki,et al.  Generation and Targeting of Human Tumor-Specific Tc1 and Th1 Cells Transduced with a Lentivirus Containing a Chimeric Immunoglobulin T-Cell Receptor , 2004, Cancer Research.